EUVIMEDEUVIMED entdecken
Open Access

Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials

Peter B Gilbert, Michal Juraska, Allan C deCamp, Shelly Karuna, Srilatha Edupuganti, Nyaradzo Mgodi, Deborah J Donnell, Carter Bentley, Nirupama Sista, Philip Andrew, Abby Isaacs, Yunda Huang und 19 weitere

Statistical Communications in Infectious Diseases · 2017

DOI: 10.1515/scid-2016-0001 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Statistical Communications in Infectious Diseases, 2017. Verfasst von Peter B Gilbert und 30 weiteren Autor:innen. Beteiligte Einrichtung: Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 102 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Anti-HIV-1 broadly neutralizing antibodies (bnAbs) have been developed as potential agents for prevention of HIV-1 infection. The HIV Vaccine Trials Network and the HIV Prevention Trials Network are conducting the Antibody Mediated Prevention (AMP) trials to assess whether, and how, intravenous infusion of the anti-CD4 binding site bnAb, VRC01, prevents HIV-1 infection. These are the first test-of-concept studies to assess HIV-1 bnAb prevention efficacy in humans.

Methods

The AMP trials are two parallel phase 2b HIV-1 prevention efficacy trials conducted in two cohorts: 2700 HIV-uninfected men and transgender persons who have sex with men in the United States, Peru, Brazil, and Switzerland; and 1500 HIV-uninfected sexually active women in seven countries in sub-Saharan Africa. Participants are randomized 1:1:1 to receive an intravenous infusion of 10 mg/kg VRC01, 30 mg/kg VRC01, or a control preparation every 8 weeks for a total of 10 infusions. Each trial is designed (1) to assess overall prevention efficacy (PE) pooled over the two VRC01 dose groups vs. control and (2) to assess VRC01 dose and laboratory markers as correlates of protection (CoPs) against overall and genotype- and phenotype-specific infection.

Results

Each AMP trial is designed to have 90 % power to detect PE > 0 % if PE is ≥ 60 %. The AMP trials are also designed to identify VRC01 properties (i. e., concentration and effector functions) that correlate with protection and to provide insight into mechanistic CoPs. CoPs are assessed using data from breakthrough HIV-1 infections, including genetic sequences and sensitivities to VRC01-mediated neutralization and Fc effector functions.

Conclusions

The AMP trials test whether VRC01 can prevent HIV-1 infection in two study populations. If affirmative, they will provide information for estimating the optimal dosage of VRC01 (or subsequent derivatives) and identify threshold levels of neutralization and Fc effector functions associated with high-level protection, setting a benchmark for future vaccine evaluation and constituting a bridge to other bnAb approaches for HIV-1 prevention.

Schlagwörter

Stichwörter der Autor:innen

Clinical trialCorrelates of protectionHIV preventionMonoclonal antibodySieve analysisSurrogate endpointVRC01

Autor:innen und Institutionen

  • Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Department of Biostatistics, University of Washington, Seattle, Washington, USA.
  • Department of Medicine, Emory University, Atlanta, Georgia, USA.
  • University of Zimbabwe - University of California San Francisco Research Program, Harare, Zimbabwe.
  • FHI 360 Durham, North Carolina, USA.
  • Department of Pediatrics, University of California, San Diego, California, USA.

Förderung

  • NIAID NIH HHS

Zitieren

APA

Gilbert, P. B., Juraska, M., deCamp, A. C., Karuna, S., Edupuganti, S., Mgodi, N., Donnell, D. J., Bentley, C., Sista, N., Andrew, P., Isaacs, A., Huang, Y., Zhang, L., Capparelli, E., Kochar, N., Wang, J., Eshleman, S. H., Mayer, K. H., Magaret, C. A., …, & Corey, L. (2017). Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials. Statistical Communications in Infectious Diseases. https://doi.org/10.1515/scid-2016-0001

Vancouver

Gilbert PB, Juraska M, deCamp AC, Karuna S, Edupuganti S, Mgodi N, et al. Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials. Statistical Communications in Infectious Diseases. 2017. doi:10.1515/scid-2016-0001

BibTeX
@article{Gilbert2017,
  author = {Gilbert, Peter B and Juraska, Michal and deCamp, Allan C and Karuna, Shelly and Edupuganti, Srilatha and Mgodi, Nyaradzo and Donnell, Deborah J and Bentley, Carter and Sista, Nirupama and Andrew, Philip and Isaacs, Abby and Huang, Yunda and Zhang, Lily and Capparelli, Edmund and Kochar, Nidhi and Wang, Jing and Eshleman, Susan H and Mayer, Kenneth H and Magaret, Craig A and Hural, John and Kublin, James G and Gray, Glenda and Montefiori, David C and Gomez, Margarita M and Burns, David N and McElrath, Julie and Ledgerwood, Julie and Graham, Barney S and Mascola, John R and Cohen, Myron and Corey, Lawrence},
  title = {Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials},
  journal = {Statistical Communications in Infectious Diseases},
  year = {2017},
  doi = {10.1515/scid-2016-0001}
}
Kostenlos starten →